Vaxxinity, Inc. VAXX
Sector:
HealthcareIndustry:
BiotechnologyDescription:
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.Recent Quarter:
2024-11-27Upcoming Quarter:
2025-03-25Annual Reports
Date2024-04-29
Revenue 0
Net Income -56,934
EPS -0.45
Basic Shares 126,509
Diluted Shares 126,508
Report Link
Date2023-03-27
Revenue 0
Net Income -75,210,000
EPS -0.6
Basic Shares 125,939,050
Diluted Shares 125,939,050
Report Link
Date2022-03-24
Revenue 66,000
Net Income -138,015,000
EPS -1.1
Basic Shares 125,392,226
Diluted Shares 125,392,226
Report Link
Date2020-12-31
Revenue 557,000
Net Income -35,377,000
EPS -0.28
Basic Shares 125,453,178
Diluted Shares 125,453,178
Report Link
Date2019-12-31
Revenue 0
Net Income -14,219,000
EPS -0.11
Basic Shares 125,453,178
Diluted Shares 125,453,178
Report Link
Annual Ratios
Date2023-12-31
PE -1.89
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -2.34
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -5.10
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -58.69
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -146.02
Dividend Yield 0.00
Payout Ratio: 0.000%
Quarterly Reports
Date2024-04-29
Revenue 0
Net Income -11,392,000
EPS -0.0895
Basic Shares 127,218,000
Diluted Shares 127,218,000
Report Link
Date2023-11-08
Revenue 0
Net Income -13,145,000
EPS -0.1
Basic Shares 126,736,784
Diluted Shares 126,736,784
Report Link
Date2023-08-09
Revenue 0
Net Income -13,977,000
EPS -0.11
Basic Shares 126,481,497
Diluted Shares 126,481,497
Report Link
Date2023-05-09
Revenue 0
Net Income -18,409,000
EPS -0.15
Basic Shares 126,061,273
Diluted Shares 126,061,273
Report Link
Date2023-03-27
Revenue 0
Net Income -20,472,000
EPS -0.16
Basic Shares 126,056,241
Diluted Shares 126,056,241
Report Link
Date2022-11-10
Revenue 0
Net Income -19,252,000
EPS -0.15
Basic Shares 126,036,865
Diluted Shares 126,036,865
Report Link
Date2022-08-11
Revenue 0
Net Income -17,280,000
EPS -0.14
Basic Shares 125,948,595
Diluted Shares 125,948,595
Report Link
Date2022-05-09
Revenue 0
Net Income -18,262,000
EPS -0.15
Basic Shares 125,709,000
Diluted Shares 125,709,613
Report Link
Date2022-03-24
Revenue -1,000
Net Income -48,191,000
EPS -0.38
Basic Shares 125,392,226
Diluted Shares 125,392,226
Report Link
Date2021-12-23
Revenue 50,000
Net Income -30,389,000
EPS -0.24
Basic Shares 125,394,115
Diluted Shares 125,453,178
Report Link
Date2021-06-30
Revenue 0
Net Income -26,910,000
EPS -0.22
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2021-03-31
Revenue 17,000
Net Income -32,021,000
EPS -0.26
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-12-31
Revenue 0
Net Income -12,719,000
EPS -0.1
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-09-30
Revenue 117,000
Net Income -16,465,000
EPS -0.13
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-06-30
Revenue 440,000
Net Income -7,061,000
EPS -0.0566
Basic Shares 124,753,178
Diluted Shares 124,753,178
Report Link
Date2020-03-31
Revenue 0
Net Income -3,711
EPS -0.11
Basic Shares 34,927
Diluted Shares 34,927
Report Link
Quarterly Ratios
Date2023-12-31
PE -2.37
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-09-30
PE -3.30
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-06-30
PE -5.70
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-03-31
PE -3.89
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -2.16
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-09-30
PE -3.24
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-06-30
PE -2.86
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-03-31
PE -7.40
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -3.65
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-09-30
PE -17.07
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-06-30
PE -19.18
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-03-31
PE -16.12
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -40.58
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-09-30
PE -31.35
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-06-30
PE -73.10
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-03-31
PE -38.94
Dividend Yield 0.00
Payout Ratio: 0.000%
RSI:
44.70Price:
$0.00Market Cap:
12,678EPS TTM:
-0.45PE Ratio:
-0.00PEPSG:
NaNFwd PE:
NaNVolume:
21,7622 Year Price Change
0.000Index 2 Year Price Change
1.5135 Year Price Change
No Price 5 Years AgoIndex 5 Year Price Change
1.906PESPG: Growth Rate of EPS projected to next quarter and 6 months trailing. Lower is better to help calculate nexts quarters PE Ratio today. Diluted shares effects the EPS reported and makes calculation show as extremely poor expected growth.
Revenue
Net Income
EPS
Shares
News
Press Releases
Notable Earnings
Please select an option: